Literature DB >> 6095854

Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat.

O H Drummer, B Jarrott.   

Abstract

The absorption and metabolism of the disulfide dimer conjugate of captopril has been studied in the rat following both oral and intravenous dosing and compared with that of the active monomer, captopril. Metabolism of the dimer to captopril has been shown after both oral and intravenous administration of the dimer (10 mg/kg) with peak plasma levels of captopril (154 ng/ml) occurring at 1 hr post dose. By contrast the peak plasma level of captopril after oral administration of captopril (10 mg/kg) at the same dose was much higher at 678 ng/ml and also occurred at 1 hr post dose. Plasma captopril disulfide species were much higher than the plasma levels of captopril after the administration of either dimer or captopril and tended to persist for much longer than for monomeric captopril particularly after administration of the dimer. Both the dimer and its pharmacologically active product captopril were found in relatively large amounts in lung, kidney and liver following the oral administration of the dimer.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095854     DOI: 10.1016/0006-2952(84)90138-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Clinical pharmacokinetics of D-penicillamine.

Authors:  P Netter; B Bannwarth; P Péré; A Nicolas
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Authors:  J Hoyer; K L Schulte; T Lenz
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

3.  Ferrous sulphate interacts with captopril.

Authors:  J P Schaefer; Y Tam; B B Hasinoff; S Tawfik; Y Peng; L Reimche; N R Campbell
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

4.  The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function.

Authors:  O H Drummer; B S Workman; P J Miach; B Jarrott; W J Louis
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.

Authors:  K L Duchin; D N McKinstry; A I Cohen; B H Migdalof
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

6.  Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo.

Authors:  Rana Rais; Randall Hoover; Krystyna Wozniak; Michelle A Rudek; Takashi Tsukamoto; Jesse Alt; Camilo Rojas; Barbara S Slusher
Journal:  Drug Metab Dispos       Date:  2012-09-04       Impact factor: 3.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.